Fig. 2

Meta-analysis of PARP2 rs878156 and breast cancer prognosis according to chemotherapy. Forest plot of of the combined hazard ratios and 95 % confidence intervals for PARP2 rs878156 in the discovery MARIE study and the replication in Breast Cancer Association Consortium (BCAC) using fixed effect model, according to treatment, i.e. no chemotherapy (a), any type of chemotherapy (b), and anthracycline-based chemotherapy (c). The associations for the BCAC studies were based on pooled analysis stratified by study and adjusted for covariables (see Methods)